Patient characteristics
| . | Treatment group . | |
|---|---|---|
| With UDCA . | Without UDCA . | |
| Patients | ||
| Total number | 123 | 119 |
| Female | 62 | 58 |
| Male | 61 | 61 |
| Age, median y (range) | 38 (5-59) | 40 (1-58) |
| Disease | ||
| AML | 38 | 34 |
| CML | 31 | 37 |
| ALL | 26 | 24 |
| MDS | 11 | 12 |
| MM | 2 | 3 |
| NHL | 2 | 2 |
| CLL | 2 | 2 |
| MF | 2 | 1 |
| ET | 0 | 1 |
| NK cell leukemia | 0 | 1 |
| HES | 1 | 0 |
| SAA | 3 | 0 |
| Fanconi | 1 | 0 |
| Amegakaryocytic thrombocytopenia | 1 | 0 |
| CGD | 1 | 1 |
| FHL | 1 | 1 |
| AGU | 1 | 0 |
| Low risk | 75 | 65 |
| High risk | 48 | 54 |
| Donor | ||
| HLA-identical sibling | 64 | 68 |
| Unrelated | 57 | 51 |
| Other family member | 2 | 0 |
| Conditioning | ||
| TBI containing | 112 | 107 |
| Cytostatic drugs only | 11 | 12 |
| Busulphan | 6 | 11 |
| ATG | 56 | 51 |
| Type of graft | ||
| Bone marrow | 97 | 93 |
| Blood stem cells | 26 | 26 |
| GVHD prophylaxis | ||
| CSA + MTX | 63 | 60 |
| CSA + MTX + MP | 57 | 55 |
| CSA + MTX + TCD | 3 | 0 |
| CSA + MP | 0 | 3 |
| MTX + MP | 0 | 1 |
| . | Treatment group . | |
|---|---|---|
| With UDCA . | Without UDCA . | |
| Patients | ||
| Total number | 123 | 119 |
| Female | 62 | 58 |
| Male | 61 | 61 |
| Age, median y (range) | 38 (5-59) | 40 (1-58) |
| Disease | ||
| AML | 38 | 34 |
| CML | 31 | 37 |
| ALL | 26 | 24 |
| MDS | 11 | 12 |
| MM | 2 | 3 |
| NHL | 2 | 2 |
| CLL | 2 | 2 |
| MF | 2 | 1 |
| ET | 0 | 1 |
| NK cell leukemia | 0 | 1 |
| HES | 1 | 0 |
| SAA | 3 | 0 |
| Fanconi | 1 | 0 |
| Amegakaryocytic thrombocytopenia | 1 | 0 |
| CGD | 1 | 1 |
| FHL | 1 | 1 |
| AGU | 1 | 0 |
| Low risk | 75 | 65 |
| High risk | 48 | 54 |
| Donor | ||
| HLA-identical sibling | 64 | 68 |
| Unrelated | 57 | 51 |
| Other family member | 2 | 0 |
| Conditioning | ||
| TBI containing | 112 | 107 |
| Cytostatic drugs only | 11 | 12 |
| Busulphan | 6 | 11 |
| ATG | 56 | 51 |
| Type of graft | ||
| Bone marrow | 97 | 93 |
| Blood stem cells | 26 | 26 |
| GVHD prophylaxis | ||
| CSA + MTX | 63 | 60 |
| CSA + MTX + MP | 57 | 55 |
| CSA + MTX + TCD | 3 | 0 |
| CSA + MP | 0 | 3 |
| MTX + MP | 0 | 1 |
AML indicates acute myeloid leukemia; CML, chronic myeloid leukemia; ALL, acute lymphatic leukemia; MDS, myelodysplastic syndrome; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; CLL, chronic lymphatic leukemia; MF, myelofibrosis; ET, essential thrombocythemia; NK, natural killer; HES, hypereosinophilic syndrome; SAA, severe aplastic anemia; CGD, chronic granulomatous disease; FHL, familial hemophagocytic lymphohistiocytosis; AGU, aspartylglucosaminuria; ATG, antithymocyte globulin; CSA, cyclosporine A; MTX, methotrexate; MP, methylprednisolone; and TCD, T-cell depletion.